ST. JOSEPH, Mich., Sept. 30 /PRNewswire/ -- GeneGo Inc., a leading provider of databases, tools and services in systems biology, announced today that they were awarded with a Phase I SBIR grant from the National Cancer Institute (NCI) for the development of a platform for understanding the influence of nutrients on cancerogenesis and cancer prevention. GeneGo will collaborate with FDA investigator, Jim Kaput Director of Personalized Nutrition and Medicine, on the project. The new platform will include a comprehensive manually curated database on nutrition, an OMICs data repository, advanced search and statistical modeling tools.
"For the last 60 years, it has been well established that cancer and nutrition are intrinsically connected," said Yuri Nikolsky, CEO of GeneGo and the grant's PI. "However, this knowledge is scattered in thousands of sources, which are difficult to annotate and categorize. We will assemble the first specialized database on the topic and develop automated tools for data analysis. The new platform will be primarily targeting healthcare professionals and nutritionists."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based
pathway analysis, cheminformatics & bioinformatics software for life
science research. The original computational MetaDiscovery(TM) platform
allows an integration and expert analysis of different kinds of
experimental data (mRNA expression, proteomics, metabolomics, microRNA
assays and other phenotypic data) and relevant bioactive chemistry
(metabolites, drugs, other xenobiotics) within the framework of curated
biological pathways and networks. GeneGo's flagship product, MetaCore
5.0(TM), assists pharmaceutical scientists in the areas of target selection
and validation, data mining in biology, identification of biomarkers for
disease states and toxicology. The second product, MetaDrug 5.0(TM) is
designed for prediction of human metabolism, toxicity and biologica
|SOURCE GeneGo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved